YSB Inc. operates a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in Chin...
YSB closed up 5.73% at HKD 4.800, driven by the 'supply assurance' sales growth narrative amid the flu season and sustained share buybacks plus executive director share increases. The stock staged a single-session rally from an intraday low of 4.500 to a high of 4.840, finishing near the session peak. Latest quarterly results showed Q4 revenue up 27.96% YoY to HKD 6.19B, net profit surging 854.93% YoY, and EPS expanding 808.18% YoY, reflecting strong margin improvement. While the stock remains 62.09% below its 52-week high of 12.66, it has reclaimed both MA20 (3.598) and MA60 (4.301), signaling a recovery from the earlier trough. However, YTD performance is still down 10.78%, suggesting uneven valuation restoration.
YSB files HKEX next-day return, share capital rises by 687,853 shares
YSB plans up to HK$ 100 million share buyback under 2026 mandate
YSB trustee buys 35,365,600 shares for 2023 share incentive plan at HK$158.76 million
YSB H1 FY26 profit attributable to owners rises 41.9% to RMB 110.84 million; revenue increases 4.5% to RMB 10.28 billion
Hong Kong's Non-Consensus Corners: Crypto ETFs and Biotech Lead the Rebound
YSB schedules board meeting to review interim results, consider dividend